Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation and Depletion (2022 - 2023)

Phathom Pharmaceuticals (PHAT) has disclosed Depreciation and Depletion for 2 consecutive years, with $200000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Depreciation and Depletion changed 0.0% to $200000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $548000.0, a N/A change, with the full-year FY2022 number at $600000.0, up 20.0% from a year prior.
  • Depreciation and Depletion was $200000.0 for Q3 2023 at Phathom Pharmaceuticals, up from $100000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $200000.0 in Q3 2022 to a low of $100000.0 in Q1 2022.